Open AccessHypoglycemic Effect of Methanolic Extract of Annona Squmosa L. (Seeds) on Streptozotocin-Induced Diabetes in Rats
The purity, safety, and long-term therapeutic efficacy of Annona squamosa L. seed extract in the treatment of diabetes were thoroughly assessed. Petroleum ether defatting and Soxhlet methanolic extraction came with the establishment of physicochemical standards (ash values). High levels of total phenolic content (TPC) and total flavonoid content (TFC), which provided notable in vitro antioxidant and anti-glycation properties, were shown by quantitative phytochemical screening. According to OECD Guideline 420 (Fixed Dose Procedure), acute oral toxicity testing verified that the extract has a broad margin of safety, showing no evidence of acute toxicity or fatality up to the highest suggested limit dose. Oral administration of Annona squamosa L. seed extract (200 mg/kg and 400 mg/kg) significantly decreased fasting blood glucose levels and reversed progressive body weight loss in an 8-week in vivo study on streptozotocin (STZ, 50–55 mg/kg)-induced diabetic Wistar rats when compared to untreated diabetic controls. The therapeutic efficacy of the 400 mg/kg dose was similar to that of normal Glibenclamide (10 mg/kg). To sum up, Annona squamosa L. seed methanolic extract is a safe, flavonoid-rich, antioxidant-rich substance that successfully reduces glycation, hyperglycemia, and weight loss in people with chronic diabetes.



